A decade of progress in kidney transplantation.
Kidney transplantation has become the treatment of choice for patients with end-stage renal disease because of better surgical techniques and the availability of more powerful immunosuppressive drugs. Regimens of immunosuppression should combine both short-term outcomes and predictors of long-term safety and survival. The value of tacrolimus for immunosuppression protocols lies in its ability to reduce the immunologic risk to the allograft and its excellent safety profile. Outcomes for kidney-transplant recipients can be further optimized by individualizing therapy to address each patient's risk profile.